Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk

OncoImmunology

Volumn 1, Issue 6, 2012, Pages 874-883

  Chinnery, Fay ^a   King, Catherine A ^a   Elliott, Tim ^a   Bateman, Andrew R ^a   James, Edward ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cross talk; Dendritic cells; Natural killer cells; Tumor immunity

Indexed keywords

HEMAGGLUTININ; INTERLEUKIN 12; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; SIALIDASE; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL CONTACT; CELL INTERACTION; CONTROLLED STUDY; DENDRITIC CELL; IMMUNIZATION; INNATE IMMUNITY; MOUSE; MUMPS VIRUS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR REJECTION;

EID: 84886944434     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20636     Document Type: Article

References (42)

1. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19:197-223; PMID:11244035; http://dx.doi.org/10.1146/annurev.immunol.19.1.197.
2. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004; 23:255-9; PMID:14685277; http://dx.doi.org/10.1038/sj.emboj.7600019.
3. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409:1055-60; PMID:11234016; http://dx.doi.org/10.1038/35059110.
4. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006; 18:151-8; PMID:16730454; http://dx.doi.org/10.1016/j.smim.2006.03.002.
5. Arnon TI, Achdout H, Lieberman N, Gazit R, Gonen-Gross T, Katz G, et al. The mechanisms controlling the recognition of tumor-and virus-infected cells by NKp46. Blood 2004; 103:664-72; PMID:14504081; http://dx.doi.org/10.1182/blood-2003-05-1716.
6. Draghi M, Pashine A, Sanjanwala B, Gendzekhadze K, Cantoni C, Cosman D, et al. NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J Immunol 2007; 178:2688-98; PMID:17312110.
7. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 2001; 31:2680-9; PMID:11536166; http://dx.doi.org/10.1002/1521-4141(200109)31:9<2680::AIDIMMU2680>3.0.CO;2-A.
8. Villar E, Barroso IM. Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview. Glycoconj J 2006; 23:5-17; PMID:16575518; http://dx.doi.org/10.1007/s10719-006-5433-0.
9. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood 2005; 106:2252-8; PMID:15933055; http://dx.doi.org/10.1182/blood-2005-03-1154.
10. + T-cell-independent pathway for antitumor CTL induction. Blood 2005; 106:338-44; PMID:15769894; http://dx.doi.org/10.1182/blood-2004-09-3775.
11. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 2005; 5:112-24; PMID:15688039; http://dx.doi.org/10.1038/nri1549.
12. Vitale M, Della Chiesa M, Carlomagno S, Pende D, Aricò M, Moretta L, et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005; 106:566-71; PMID:15784725; http://dx.doi.org/10.1182/blood-2004-10-4035.
13. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5:405-11; PMID:10202929; http://dx.doi.org/10.1038/7403.
14. Mocikat R, Braumüller H, Gumy A, Egeter O, Ziegler H, Reusch U, et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003; 19:561-9; PMID:14563320; http://dx.doi.org/10.1016/S1074-7613(03)00264-4.
15. Campos-Martín Y, Colmenares M, Gozalbo-López B, López-Núñez M, Savage PB, Martínez-Naves E. Immature human dendritic cells infected with Leishmania infantum are resistant to NK-mediated cytolysis but are efficiently recognized by NKT cells. J Immunol 2006; 176:6172-9; PMID:16670326.
16. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Münz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002; 195:343-51; PMID:11828009; http://dx.doi.org/10.1084/jem.20011149.
17. Elboim M, Gazit R, Gur C, Ghadially H, Betser-Cohen G, Mandelboim O. Tumor immunoediting by NKp46. J Immunol 2010; 184:5637-44; PMID:20404273; http://dx.doi.org/10.4049/jimmunol.0901644.
18. Halfteck GG, Elboim M, Gur C, Achdout H, Ghadially H, Mandelboim O. Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J Immunol 2009; 182:2221-30; PMID:19201876; http://dx.doi.org/10.4049/jimmunol.0801878.
19. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 2009; 119:1251-63; PMID:19349689; http://dx.doi.org/10.1172/JCI36022.
20. Cagnano E, Hershkovitz O, Zilka A, Bar-Ilan A, Golder A, Sion-Vardy N, et al. Expression of ligands to NKp46 in benign and malignant melanocytes. J Invest Dermatol 2008; 128:972-9; PMID:17972960; http://dx.doi.org/10.1038/sj.jid.5701111.
21. Mistry AR, O'Callaghan CA. Regulation of ligands for the activating receptor NKG2D. Immunology 2007; 121:439-47; PMID:17614877; http://dx.doi.org/10.1111/j.1365-2567.2007.02652.x.
22. Noone CM, Lewis EA, Frawely AB, Newman RW, Mahon BP, Mills KH, et al. Novel mechanism of immunosuppression by influenza virus haemagglutinin: selective suppression of interleukin 12 p35 transcription in murine bone marrow-derived dendritic cells. J Gen Virol 2005; 86:1885-90; PMID:15958666; http://dx.doi.org/10.1099/vir.0.80891-0.
23. Yao Q, Zhang R, Guo L, Li M, Chen C. Th cellindependent immune responses to chimeric hemagglutinin/ simian human immunodeficiency viruslike particles vaccine. J Immunol 2004; 173:1951-8; PMID:15265929.
24. Horga MA, Macip S, Tuyama AC, Tan MC, Gusella GL. Human parainfluenza virus 3 neuraminidase activity contributes to dendritic cell maturation. Viral Immunol 2005; 18:523-33; PMID:16212531; http://dx.doi.org/10.1089/vim.2005.18.523.
25. Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 2004; 104:3267-75; PMID:15242871; http://dx.doi.org/10.1182/blood-2004-01-0380.
26. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 2000; 1:433-40; PMID:11062504; http://dx.doi.org/10.1038/80877.
27. Raulet DH. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 2004; 5:996-1002; PMID:15454923; http://dx.doi.org/10.1038/ni1114.
28. + T cell priming. J Immunol 2006; 177:2969-75; PMID:16920932.
29. Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier S, Lazo S, et al. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clin Cancer Res 1996; 2:493-9.
30. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004; 24:1861-71; PMID:15274367.
31. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105:3051-7; PMID:15632206; http://dx.doi.org/10.1182/blood-2004-07-2974.
32. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004; 18:1835-8.
33. Alici E, Sutlu T, Björkstrand B, Gilljam M, Stellan B, Nahi H, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMPcompliant components. Blood 2008; 111:3155-62; PMID:18192509; http://dx.doi.org/10.1182/blood-2007-09-110312.
34. Milani V, Stangl S, Issels R, Gehrmann M, Wagner B, Hube K, et al. Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy-a case report. J Transl Med 2009; 7:50; PMID:19549307; http://dx.doi.org/10.1186/1479-5876-7-50.
35. Park YK, Shin DJ, Cho D, Kim SK, Lee JJ, Shin MG, et al. Interleukin-21 increases direct cytotoxicity and IFN? production of ex vivo expanded NK cells towards breast cancer cells. Anticancer Res 2012; 32:839-46; PMID:22399602.
36. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002; 195:327-33; PMID:11828007; http://dx.doi.org/10.1084/jem.20010938.
37. Sanchez-Perez L, Kottke T, Daniels GA, Diaz RM, Thompson J, Pulido J, et al. Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol 2006; 177:4168-77; PMID:16951382.
38. + memory T cell differentiation. PLoS One 2010; 5:13740; PMID:21060788; http://dx.doi.org/10.1371/journal.pone.0013740.
39. Novy P, Quigley M, Huang X, Yang Y. CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses. J Immunol 2007; 179:8243-51; PMID:18056368.
40. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 2004; 5:1143-8; http://dx.doi.org/10.1038/ni1129; PMID:15475958.
41. Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K, et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor celltumor cell fusion. Cancer Res 2002; 62:5495-504; PMID:12359759.
42. Tsurudome M, Yamada A, Hishiyama M, Ito Y. Monoclonal antibodies against the glycoproteins of mumps virus: fusion inhibition by anti-HN monoclonal antibody. J Gen Virol 1986; 67:2259-65; PMID:3760826; http://dx.doi.org/10.1099/0022-1317-67-10-2259.